Challenges in the Treatment of Sarcomas of Adolescents and Young Adults
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jun 2017 · 1 min read
In brief
In brief
Adolescent and young adult sarcoma patients experience worse outcomes than younger patients due to distinct tumor biology, higher treatment toxicity, and psychosocial barriers including financial strain and treatment adherence challenges. Low clinical trial participation limits development of age-appropriate protocols and biospecimen collection for research.
Written by the GCMD Library team from the article.
Statements in this article
Adolescent and young adult sarcoma patients do not fare as well as their younger counterparts.
Compared to younger patients, AYA patients often develop genetically distinct tumors.
AYA patients are more likely to suffer characteristic therapy-related toxicities compared to younger patients.
Lack of clinical trial participation among AYA patients has slowed the establishment of optimized age-specific treatment protocols.
The relative rarity of sarcomas among adult cancers may limit the familiarity of oncologists with state of the art diagnostic and therapeutic aspects of sarcomas in young adults.
Improved enrollment on clinical trials is a critical step in addressing the challenges faced by AYA patients.